Lakefront Biotherapeutics names Dr. Mehdi Shahidi to board

Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) announced on November 2, 2026 the appointment by co-optation of Dr. Mehdi Shahidi as Non-Executive Independent Director to its Board of Directors, effective that day.¹ He replaces Dr. Paulo Fontoura, who resigned from the Board in July 2026 after being named Global Head of R&D at Sanofi SA.¹

Board Chair Gino Santini said the company expects Shahidi's experience to help guide Lakefront as it works to advance its pipeline, which the company's statement ties to gamgertamig and its preclinical assets, while maintaining a disciplined approach to deploying its strategic capital.¹

According to the biography included in the release, Shahidi is a physician-scientist with more than 20 years of biopharma experience across translational research, clinical development, regulatory affairs, and the introduction of medicines to patients worldwide.¹ He currently serves as Head of Development and Chief Medical Officer at Ottimo Pharma, as a Venture Partner at Medicxi, and as a founder of Petalion Therapeutics.¹ He previously was SVP, Global Head of Medicine and CMO at Boehringer Ingelheim, where he oversaw a large global organization with a broad therapeutic mandate.¹ He also served on the Supervisory Board of CureVac through its acquisition by BioNTech, as well as on innovation committees at EFPIA, TransCelerate, and the PhRMA R&D Leadership Forum.¹ He is a clinical oncologist and GMC-registered specialist in pharmaceutical medicine who trained in oncology at the Royal Marsden Hospital and conducted clinical research at the Institute of Cancer Research in London.¹

Lakefront describes itself as a biotechnology company building a pipeline of medicines for serious diseases, with a clinical-stage portfolio in immunology and inflammation anchored by gamgertamig, described as a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases.¹ The appointment was disclosed in a Form 6-K filed with the SEC for the month of November 2026.